UR TV CAST

Then again, one speaker does takes up less room, and there is something slightly Star Trek about its perspex shield – all the better to hear it with, because in order to create a stereo effect, music is bounced off the screen and around your room. Don’t expect to put the results on your mantelpiece, but for computer viewing the quality is pretty impressive.Sony SRS-RF80RK, £150, 0870 511 1999; has Sony created this tower of sound? Perhaps it is simply because it can. What makes the camera worth a second look is its built-in flash: for the first time you can take pictures in low light (and send them via MMS or e-mail). But it really isn’t as scary as you may think, and you might even have some fun. The S55’s Quickpic camera comes as an attachment, so when not snapping you’ve got a great-looking compact phone. While everyone is banging on about video messaging, most of us haven’t even got our heads around the concept of taking and sending photos with our phones. Prior to that, director of research at Searle UK Research Laboratories.

Chief executives of 59 are not going to bring in a lot of new thinking.”PETER FELLNER – BIOTECH BOFFINTitle: Chairman-designate, Celltech; chairman, British Biotech.Age: 59.Pay: Celltech salary £420,000 in 2001 with £370,000 bonus. When Mr Ando finally gets to Celltech, Mr Fellner can move up to the chairmanship, freeing himself to take a more hands-on role at British Biotech. The rise to Celltech chairman is, Mr Fellner says, a natural progression for a man with experience in academic research and then as a business executive “This is a youngish man’s business. It has to be because it is based on innovation, and you need turnover at the top to change some of the thinking patterns. Even though everybody knows it is Goran Ando, currently head of research and development at Pharmacia of the US, he still works for that company and has to hang on until its takeover by Pfizer is completed.The delay is having knock-on effects across the industry. My successor has the same view.”"My successor” has to be discussed in these anonymous terms because he has not been officially named.

Such acquisitions are the best way to create a global drug company. The Celltech bid is less than the value of the cash in OGS so, provided Mr Fellner can close most of its operations cost-effectively, Celltech will be getting the OGS library of human proteins free.The real focus for Celltech is on a big takeover of a US company, perhaps worth up to $500m (£320m). In 2003, the focus is on cash and what investors want is cashflow that can fund the innovation.”It was this focus on cash that drew Celltech’s attention to OGS. Until then, I think that late Nineties model is unattractive.

You don’t want something that is going to burn the GDP of Guatemala. What British Biotech has to offer is a lot of cash for its size (it will have a pile of more than £50m), a clinical development capability and some management expertise. On Friday, British Biotech tied up an all-share acquisition of RiboTargets, a private firm run by Mr Fellner’s old colleague from Celltech, Simon Sturge. British Biotech was brought to its knees in the late Nineties by the failure of what the company had hoped would be its “cure for cancer”, a drug called Marimastat; RiboTargets has drug discovery technology that, if all goes to plan, will give British Biotech’s scientists a second shot at developing useful medical products.This first deal was easy, but now Mr Fellner hopes to slash costs at the merged group and use it as the “nucleus” of a much bigger biotech enterprise. “Only in as far as people might say I have been involved more than most people in merger and acquisition activity, while you have got a sector in urgent need of consolidation,” he says.But, if successful, his arrival at British Biotech will transform the sector.